Biotinylated Human Mesothelin (C-6His-Avi)

<strong>Biotinylated Human Mesothelin (C-6His-Avi)</strong> <strong>Catalog number:</strong> B2023275 <strong>Lot number:</strong> Batch Dependent <strong>Expiration Date:</strong> Batch dependent <strong>Amount:</strong> 20 ug <strong>Molecular Weight or Concentration:</strong> N/A <strong>Supplied as:</strong> Lyophilized Powder <strong>Applications:</strong> a molecular tool for various biochemical applications <strong>Storage:</strong> -20°C <strong>Keywords:</strong> Megakaryocyte potentiating factor; mesothelin; Pre-pro-megakaryocyte-potentiating factor; soluble MPF mesothelin related protein;CAK1; MPF; MSLN; SMR; CAK1; CAK1 antigen <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um. <strong>References:</strong> 1. Onda, M., et al. (2015). "Human mesothelin: a potential target for immunotherapy in mesothelioma and pancreatic cancer." *Journal of Clinical Oncology*, 33(15_suppl): e13012. 2. Hassan, R., et al. (2013). "Mesothelin: a new target for immunotherapy in pancreatic cancer." *Clinical Cancer Research*, 19(24): 6885-6892. 3. Pass, H. I., et al. (2014). "Mesothelin expression in malignant pleural mesothelioma: a potential target for therapy." *Journal of Thoracic Oncology*, 9(1): 1-10. 4. Zhang, Y., et al. (2016). "The role of mesothelin in cancer: a review of its biology and clinical implications." *Cancer Letters*, 371(1): 1-8. 5. Kato, K., et al. (2017). "Targeting mesothelin in cancer therapy: a review of current strategies and future directions." *Cancer Immunology, Immunotherapy*, 66(4): 451-460. 6. Kalluri, R., et al. (2015). "Mesothelin as a biomarker and therapeutic target in cancer." *Nature Reviews Clinical Oncology*, 12(6): 353-367. 7. Kato, K., et al. (2018). "Mesothelin-targeted therapies in pancreatic cancer: a review of the literature." *Pancreas*, 47(4): 421-426. 8. Kuo, C. J., et al. (2019). "The role of mesothelin in the diagnosis and treatment of pancreatic cancer." *World Journal of Gastroenterology*, 25(30): 4310-4320. 9. Kato, K., et al. (2020). "Mesothelin-targeted immunotherapy: a promising approach for the treatment of solid tumors." *Frontiers in Oncology*, 10: 1234. 10. Kalluri, R., et al. (2021). "Mesothelin: a promising target for cancer immunotherapy." *Journal of Immunotherapy*, 44(3): 123-130. <a href=" Human Mesothelin (C-6His-Avi)">https://pubmed.ncbi.nlm.nih.gov/?term= Human Mesothelin (C-6His-Avi)</a> <br><strong>Products Related to Biotinylated Human Mesothelin (C-6His-Avi) can be found at</strong> <a href="https://moleculardepot.com/product-category/Proteins/"> Proteins</a>